| Literature DB >> 33408874 |
Wolfgang Kemmler1, Matthias Kohl2, Simon von Stengel1, Daniel Schoene1.
Abstract
OBJECTIVES: Sarcopenia is related to the metabolic syndrome (MetS), a cluster of cardiometabolic risk-factors (CRF). Most exercise trials apply aerobic rather than resistance exercise to address CRF, while the strategy for maintaining muscle and bone is the opposite. However, there is considerable evidence that resistance exercise positively affects CRF. In the present study, we determined the effect of high-intensity resistance exercise training (HIT-RT) on CRF represented by the MetS in older men.Entities:
Keywords: cardiovascular; exercise physiology; exercise rehabilitation; old; sports rehabilitation programmes
Year: 2020 PMID: 33408874 PMCID: PMC7768961 DOI: 10.1136/bmjsem-2020-000846
Source DB: PubMed Journal: BMJ Open Sport Exerc Med ISSN: 2055-7647
Figure 1Participant flow through the study. CG, control group; FranSO: Franconian Sarcopenic Obesity trial; HIT-RT, high-intensity resistance exercise training; ITT, intention-to-treat; SMI: skeletal muscle mass index.
Baseline characteristics of the CG and HIT-RT groups
| Variable | CG | HIT-RT | P value |
| Age (years) | 79.2±4.7 | 77.8±3.6 | 0.262 |
| Body mass index (kg/m2)* | 24.5±1.9 | 25.0±3.0 | 0.515 |
| Body fat rate (DXA) (%)† | 34.5±6.1 | 33.6±4.0 | 0.563 |
| LBM (kg/m2)† | 6.89±0.31 | 7.01±0.27 | 0.671 |
| MetS-prevalence (n) | 7 | 8 | 0.666 |
| Diabetes mellitus type II (n) | 1 | 1 | 0.960 |
| Hypertension (n)‡ | 7 | 11 | 0.172 |
| Physical activity (index)§ | 4.15±1.53 | 4.45±1.32 | 0.490 |
| Regular exercise ≥1×week (n) | 5 | 5 | 0.931 |
| ¶ALEF, LLFDI (index)¶ | 1.73±0.82 | 1.87±1.05 | 0.646 |
| 25(OH)D (nmol/L)** | 54.0±21.1 | 43.8±17.5 | 0.126 |
| Energy intake (MJ/day)†† | 9.39±2.42 | 8.84±1.71 | 0.407 |
| Smokers (n) | 4 | 3 | 0.959 |
*Via bio impedance analysis.
†Via dual-energy X-ray absorptiometry (DXA, hological QDR 4500a, USA).
‡Mean arterial blood pressure>106.7 RR.
§Scale from (1) very low to (7) very high.51
¶‘Advanced lower extremity function’, late life function disability instrument52: (scale from (1) ‘no problem’ to (5) ‘impossible’).
**Serum concentrations of 25(OH)D were measured using a Roche Modular E170 Analyzer and an electro-chemiluminescence immunoassay (ECLIA; Roche Diagnostics, Penzberg, Germany).
††As determined by a 4-day dietary record.
CG, control group; DXA, dual energy X-ray absorptiometry; HIT-RT, high-intensity resistance exercise training; LBM, Lean Body Mass; MetS, metabolic syndrome.
Baseline data and changes of the MetS-Z score in the CG and HIT-RT along with corresponding between group differences
| CG | HIT-RT | Difference | P value | |
| MetS-Z score (Z) | ||||
| Baseline | −4.22±3.70 | −3.14±4.66 | – | 0.322 |
| Changes | 0.80±1.71* | −0.88±1.33* | 1.68 (0.73 to 2.65) | 0.001 |
*p<0.05.
CG, control group; HIT-RT, high-intensity resistance exercise training; MetS, metabolic syndrome; MV, mean value; SD, standard deviation.
Baseline data and changes of selected parameters constituting the metabolic syndrome according to IDF13
| CG | HIT-RT | Difference | P value | |
| Waist circumference (cm) | ||||
| Baseline | 89.2±8.9 | 92.4±11.1 | – | 0.306 |
| Changes | 1.12±2.16* | −1.85±2.17*** | 2.97 (1.59 to 4.36) | <0.001 |
| Mean arterial blood pressure (MAP) (mm Hg) | ||||
| Baseline | 99.1±8.6 | 103.0±6.8 | – | 0.114 |
| Changes | 4.05±5.87** | −1.73±5.95 | 5.78 (2.08 to 9.47) | 0.003 |
| HDL-cholesterol (HDL-C) (mg/dL) | ||||
| Baseline | 60.2±14.0 | 54.4±12.3 | – | 0.165 |
| Changes | 0.25±11.1 | 6.09±9.40* | 6.09 (0.01 to 11.67) | 0.049 |
*p<0.05; **p<0.01; ***p<0.001.
CG, control group; HIT-RT, high-intensity resistance exercise training; MV, mean value; SD, standard deviation.